Jeannette Y. Lee

Jeannette Y. Lee

Auto-generated profile, based on publicly available information

Jeannette Y. Lee

University of Arkansas for Medical Sciences, Little Rock, AR

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in Medical Care
Verified
Journal Article
Closed access
PCPaul J. Catalano
Paul J. Catalano
JAJohn Z. Ayanian
John Z. Ayanian
JWJane C. Weeks
Jane C. Weeks
KKKatherine L. Kahn
Katherine L. Kahn
MLMary Beth Landrum
Mary Beth Landrum
DHDavid P. Harrington
David P. Harrington
Background The research goals of the Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium are to determine how characteristics and beliefs of patients, providers, and health care organizations influence the treatments and outcomes of individuals with newly diagnosed lung and colorectal cancers. As CanCORS results will inform national policy, it is important to know how they generalize to the United States population with these cancers. Research Design This study assessed the representativeness of the CanCORS cohort of 10,547 patients with lung cancer (LC) or colorectal cancer (CRC) enrolled between 2003 and 2005. We compared characteristics (sex, race, age, and disease stage) with the Surveillance, Epidemiology, and End Results (SEER) population of 234,464 patients with new onset of these cancers during the CanCORS recruitment period. Results The CanCORS sample is well matched to the SEER Program for both cancers. In CanCORS, 41% LC/47% CRC were female versus 47% LC/49% CRC in SEER. African American, Hispanic, and Asian cases differed by no more than 5 percentage points between CanCORS and SEER. The SEER population is slightly older, with the percentage of patients older than 75 years 33.1% LC/37.3% CRC in SEER versus 26.9% LC/29.4% in CanCORS, and also has a slightly higher proportion of early stage patients. We also found that the CanCORS cohort was representative within specific SEER regions that map closely to CanCORS sites. Conclusions This study demonstrates that the CanCORS Consortium was successful in enrolling a demographically representative sample within the CanCORS regions.


10 January 2022 in Contemporary Clinical Trials
Verified
Journal Article
Open access
JLJeannette Y. Lee
Jeannette Y. Lee
SLShelly Y. Lensing
Shelly Y. Lensing
JBJ. Michael Berry-Lawhorn
J. Michael Berry-Lawhorn
NJNaomi Jay
Naomi Jay
TDTeresa M. Darragh
Teresa M. Darragh
JPJoel Palefsky
Joel Palefsky
It is well established that persons living with HIV (PLWH) have highly elevated rates of anal HSIL and anal cancer compared with those who are not living with HIV. The 5-year risk of anal cancer following anal HSIL has been reported to be as high as 14.1% among PLWH compared with 3.2% among those who are not living with HIV.

1 June 2019 in Papillomavirus Research
Verified
Journal Article
Open access
JKJessica A. Kahn
Jessica A. Kahn
MBMarvin Belzer
Marvin Belzer
XCXiaofei Chi
Xiaofei Chi
JLJeannette Lee
Jeannette Lee
AGAditya H. Gaur
Aditya H. Gaur
JPJoel Palefsky
Joel Palefsky
The aims of this study were to: 1) determine prevalence of anogenital and oral HPV, 2) determine concordance between HPV at anal, perianal, scrotal/penile, and oral sites; and 3) describe factors associated with anogenital HPV types targeted by the 9-valent vaccine. Data were collected from 2012 to 2015 among men who have sex with men 18-26 years of age enrolled in a vaccine trial (N = 145). Penile/scrotal, perianal, anal, and oral samples were tested for 61 HPV types. Logistic regression was used to identify factors associated with types in the 9-valent vaccine. Participants' mean age was 23.0 years, 55.2% were African-American, and 26.2% were Hispanic; 93% had anal, 40% penile, and 6% oral HPV. Among those with anogenital infection, 18% had HPV16. Concordance was low between anogenital and oral sites. Factors independently associated with a 9-valent vaccine-type HPV were: race (African-American vs. White, OR=2.67, 95% CI=1.11-6.42), current smoking (yes vs. no, OR=2.37, 95% CI=1.03-5.48), and number of recent receptive anal sex partners (2+ vs. 0, OR=3.47, 95% CI=1.16-10.4). Most MSM were not infected with HPV16 or HPV18, suggesting that they may still benefit from HPV vaccination, but anogenital HPV was very common, highlighting the importance of vaccinating men before sexual initiation. CLINICAL TRIAL NUMBER: NCT01209325.

9 December 2009 in Clinical Trials
Verified
Journal Article
Open access
PDF file
JLJeannette Lee
Jeannette Lee
GAGerald Andriole
Gerald Andriole
AAAndrew Avins
Andrew Avins
ECE David Crawford
E David Crawford
HFHarris Foster
Harris Foster
MBMichael Barry
Michael Barry
Background Benign prostatic hyperplasia (BPH), a common condition among older men, confers its morbidity through potentially bothersome lower urinary tract symptoms. Treatments for BPH include drugs such as alpha-adrenergic receptor blockers and 5-alpha reductase inhibitors, minimally invasive therapies that use heat to damage or destroy prostate tissue, and surgery including transurethral resection of the prostate. Complementary and alternative medicines are gaining popularity in the US. Two phytotherapies commonly used for BPH are extracts of the fruit of Serenoa repens, the Saw palmetto dwarf palm that grows in the Southeastern US, and extracts of the bark of Pygeum africanum, the African plum tree. Purpose The objective of the Complementary and Alternative Medicines for Urological Symptoms (CAMUS) clinical trial is to determine if phytotherapy is superior to placebo in the treatment of BPH. Methods CAMUS was originally designed as a 3300-participant, four-arm trial of S. repens, P. africanum, an alpha-adrenergic blocking drug, and placebo with time to clinical progression of BPH, a measure of long-term efficacy, as the primary endpoint. Before enrollment started, a randomized, double-blind, placebo-controlled, single institution clinical trial showed that S. repens at the usual dose did not demonstrate any benefit over placebo with respect to symptom relief at 1 year. Consequently, the focus of CAMUS shifted from evaluating long-term efficacy to determining if any short-term (6—18 months) symptom relief could be achieved with increasing doses of S. repens, the phytotherapy most commonly used in the US for BPH. Results Results are anticipated in 2011. Conclusions Trial design occurs in an environment of continually evolving information. In this case, emerging results from another trial suggested that a study of long-term efficacy was premature, and that an effective dose and preparation of S. repens had to be established before proceeding to a long-term clinical trial. Clinical Trials 2009; 6: 628—636. http://ctj.sagepub.com

18 September 2014 in Blood
Verified
Journal Article
Open access
PDF file
SEStephen W. Erickson
Stephen W. Erickson
VRVinay R. Raj
Vinay R. Raj
OSOwen W. Stephens
Owen W. Stephens
IDIshwori Dhakal
Ishwori Dhakal
SCShweta S. Chavan
Shweta S. Chavan
AVAnnette J. Vangsted
Annette J. Vangsted